|
MAP4K3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63402624764331E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.7888024395063E-11 |
| Normal-vs-Stage2 |
1.79185999999998E-05 |
| Normal-vs-Stage3 |
1.72561964717488E-12 |
| Normal-vs-Stage4 |
1.73094871769308E-12 |
| Stage1-vs-Stage2 |
9.045600E-01 |
| Stage1-vs-Stage3 |
5.368300E-02 |
| Stage1-vs-Stage4 |
1.90794999999078E-05 |
| Stage2-vs-Stage3 |
1.775980E-01 |
| Stage2-vs-Stage4 |
1.106100E-02 |
| Stage3-vs-Stage4 |
4.680400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.68514116391816E-14 |
| Normal-vs-AfricanAmerican |
1.193450E-04 |
| Normal-vs-Asian |
2.16799999996908E-06 |
| Caucasian-vs-AfricanAmerican |
7.719000E-01 |
| Caucasian-vs-Asian |
6.441800E-01 |
| AfricanAmerican-vs-Asian |
9.629600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.66030000648254E-10 |
| Normal-vs-Female |
2.04303240991521E-12 |
| Male-vs-Female |
5.617200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.67080004965482E-09 |
| Normal-vs-Age(41-60Yrs) |
6.46105391410856E-12 |
| Normal-vs-Age(61-80Yrs) |
5.07240027758371E-10 |
| Normal-vs-Age(81-100Yrs) |
2.967300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.374000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.988790E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.887560E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.392400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.790000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.106000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.667570E-02 |
| Classical-VS-Follicular |
5.908200E-01 |
| Classical-VS-Other |
5.582800E-01 |
| Classical-VS-Normal |
1.55339999752258E-08 |
| Tall-VS-Follicular |
1.872580E-01 |
| Tall-VS-Other |
2.184800E-01 |
| Tall-VS-Normal |
2.48819964632219E-10 |
| Follicular-VS-Other |
5.445200E-01 |
| Follicular-VS-Normal |
9.78859999722914E-08 |
| Other-VS-Normal |
5.268100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.91306995087371E-12 |
| Normal-vs-N1 |
3.26369999914533E-08 |
| N0-vs-N1 |
6.333800E-01 |
|
|
